Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval from the United States Food & Drug Administration (FDA) for voriconazole tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).
Industry News
-
-
Teva Pharmaceutical Industries Ltd launch Zecuity, the first and only patch system in US designed to provide relief from migraine. Zecuity is a single-use, disposable patch system that delivers sumatriptan through the skin. Zecuity is a prescription medicine used for the acute treatment of migraine headaches with or without aura in adults.
-
Sandoz, a Novartis company and a global leader in generic pharmaceuticals launch of first biosimilar Zarxio (filgrastim-sndz). Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA).
-
Honeywell, a diversified technology and manufacturing leader, introduced Safyr, a high-moisture barrier thermoformable film designed specifically to meet the requirements of India’s domestic pharmaceutical packaging market.
-
Glenmark Pharmaceuticals S.A., GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. Glenmark has now completed clinical phase I studies for GBR 830 in the Netherlands.
[adsense:336x280:8701650588]
-
Amgen, a biopharmaceutical company, has entered a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration also enables Amgen to focus on the commercialisation of its migraine programmes in the US, Canada and Japan, while leveraging Novartis' strong commercial capabilities in neuroscience throughout Europe and other markets worldwide.
-
BPL Medical Technologies Private Ltd announced the acquisition of Penlon Ltd, a UK-based leading global manufacturer of anaesthesia systems and vaporisers with worldwide distribution networks.
-
(NewsVoir); The Herbalife Family Foundation (HFF), a non-profit organization dedicated to improving the lives of children by helping charitable organizations provide healthy nutrition to children in need, today announced the launch of the third phase of Casa Herbalife program with Smile Foundation, a national development organization that works for underprivileged children and youth in education, healthcare, livelihoods and women’s empowerment. During the third phase unveiled today in Bangalore, the HFF will extend grants to provide nutritional support to 1,000 children across India, through Smile Foundation’s ‘Mission Education’ program.
-
Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is announced the appointment of Umang Vohra as Global Chief Financial and Strategy Officer and Prabir Jha as Global Chief People Officer effective 1st October 2015.
-
~ Through the acquisition of InvaGen, Cipla gains scale in the US generics market with a strong manufacturing and R&D base, access to broad product portfolio and a strong customer base consisting of top wholesalers/retailers
~ Through the acquisition of Exelan, Cipla gains access to the government and institutional market in the US
Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction being subject to certain closing conditions, is valued at $550 million and will be an all cash transaction. The combined revenue from these transactions is over $200 million for the year ended Dec 2014 and over $225 million in LTM June 2015.
Subscribe with us
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
